Skip to main content
SpringerLink
Log in

Decitabine

  • Chapter
  • First Online:
Small Molecules in Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 201))

Abstract

Besides 5-azacytidine (azacitidine, Vidaza®), 5-aza-2′-deoxycytidine (decitabine, Dacogen®) is the most widely used inhibitor of DNA methylation, which triggers demethylation leading to consecutive reactivation of epigenetically silenced tumor suppressor genes in vitro and in vivo. Although antileukemic activity of decitabine is known for almost 40 years, its therapeutic potential in hematologic malignancies has only recently led to its approval in higher-risk MDS patients and as first-line treatment in AML patients >65 years who are not candidates for intensive chemotherapy. Several clinical trials showed promising activity of low-dose decitabine also in CML and hemoglobinopathies, whereas its efficacy in solid tumors is very limited. Clinical responses appear to be exerted both by epigenetic alterations and by induction of cell-cycle arrest and/or apoptosis. Recent and ongoing clinical trials investigate new dosing schedules, routes of administration, and combination of decitabine with other agents, including histone deacetylase inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, Jäger E, Lübbert M (2010) The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res 34:899–905

    PubMed  CAS  Google Scholar 

  • Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schätzlein A, Twelves C, Kaye SB, Brown R (2007) Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25:4603–4609

    PubMed  CAS  Google Scholar 

  • Baylin SB, Herman JG, Vertino PM, Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Cancer Res 72:141–196

    CAS  Google Scholar 

  • Baylin SB (2002) Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol 12:331–337

    PubMed  CAS  Google Scholar 

  • Bhalla KN (2005) Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23:3971–3993

    PubMed  CAS  Google Scholar 

  • Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25:3884–3891

    PubMed  CAS  Google Scholar 

  • Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G (2010) Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 107:7473–7478

    PubMed Central  PubMed  CAS  Google Scholar 

  • Bodey B (2002) Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy. Expert Opin Biol Ther 2:577–584

    PubMed  CAS  Google Scholar 

  • Bogani C, Ponziani V, Guglielmelli P, Desterke C, Rosti V, Bosi A, Le Bousse-Kerdiles MC, Barosi G, Vannucchi AM (2008) Hypermethylation of CXCR4 promotor in CD34+ cells from patients with primary myelofibrosis. Stem Cells 26:1920–1930

    PubMed  CAS  Google Scholar 

  • Boivin AJ, Momparler LF, Hurtubise A, Momparler RL (2002) Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs 13:869–874

    PubMed  CAS  Google Scholar 

  • Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Katarjian H (2008) Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 49:690–695

    PubMed Central  PubMed  CAS  Google Scholar 

  • Calabro L, Fonsatti E, Altomonte M, Pezzani L, Colizzi F, Nanni P, Gattei V, Sigalotti L, Maio M (2005) Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications. J Cell Physiol 202:474–477

    PubMed  CAS  Google Scholar 

  • Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103–107

    PubMed  CAS  Google Scholar 

  • Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J (2008) Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 61:759–766

    PubMed  CAS  Google Scholar 

  • Cashen AF, Schiller GJ, O’Donnell MR, DiPersio JF (2010) Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 28:556–561

    PubMed  CAS  Google Scholar 

  • Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA, Selker EU (2003) Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95:399–409

    PubMed  CAS  Google Scholar 

  • Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, Marquez VE, Jones PA (2004) Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 24:1270–1278

    PubMed Central  PubMed  CAS  Google Scholar 

  • Choi SH, Byun HM, Kwan JM, Issa JP, Yang AS (2007) Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br J Haematol 138:616–623

    PubMed  CAS  Google Scholar 

  • Coral S, Sigalotti L, Altomonte M, Engelsberg A, Colizzi F, Cattarossi I, Maraskovsky E, Jager E, Seliger B, Maio M (2002) 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell caricoma: immunotherapeutic implications. Cancer Res 8:2690–2695

    CAS  Google Scholar 

  • Coral S, Sigalotti L, Colizzi F, Spessotto A, Nardi G, Cortini E, Pezzani L, Fratta E, Fonsatti E, Di Giacomo AM, Nicotra MR, Natali PG, Altomonte M, Maio M (2006) Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J Cell Physiol 207:58–66

    PubMed  CAS  Google Scholar 

  • Creusot F, Acs G, Christman JK (1982) Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biol Chem 257:2041–2048

    PubMed  CAS  Google Scholar 

  • Danilov AV, Relias V, Feeney DM, Miller KB (2009) Decitabine is an effective treatment of idiopathic meylofibrosis (Correspondence). Brit J Haematol 145:131–132

    Google Scholar 

  • Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, Jones PA, Lübbert M (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100:2957–2964

    PubMed  CAS  Google Scholar 

  • Debusscher L, Marie JP, Dodion P, Blanc GM, Arrigo C, Zittoun R, Stryckmans P (1990) Phase-I-II trial of 5-aza-2′-deoxycytidine in adult patients with acute leukemia. In: Momparler RL, de Vos D (eds) 5-Aza-2′-deoxycytidine: preclinical and clinical studies. PCH, Haarlem, The Netherlands, pp 131–142

    Google Scholar 

  • De Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H (2003) Long-term follow up of a phase I study of high-dose Decitabine, Busulfan, and Cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 97:1242–1247

    PubMed  Google Scholar 

  • De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, Davisson J, Garcia-Manero G, Champlin R, Issa J-P, Ravandi F (2009) Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43:839–843

    Google Scholar 

  • DeSimone J, Koshy M, Dorn L, Lavelle D, Bressler L, Molokie R, Talischy N (2002) Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 99:3905–3908

    PubMed  CAS  Google Scholar 

  • Smet De, Lurquin C, Lethe B, Martelange V, Boon T (1999) DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19:7327–7335

    PubMed Central  PubMed  Google Scholar 

  • D’Incalci M, Covey JM, Zaharko DS, Kohn KW (1985) DNA alkali-labile sites induced by incorporation of 5-aza-2′-deoxycytidine into DNA of mouse leukemia L1210 cells. Cancer Res 45:3197–3202

    PubMed  Google Scholar 

  • Dodion PF, Clavel M, ten Bokkel Huinink W, Robinson E, Renard JF (1990) Phase-II trials with 2′-deoxy-5-azacytidine conducted by the Early Clinical Trials group of the EORTC. In: Momparler RL, de Vos D (eds) 5-Aza-2′-deoxycytidine: preclinical and clinical studies. PCH, Haarlem, The Netherlands, pp 117–124

    Google Scholar 

  • Driscoll JS, Marquez VE, Plowman J, Liu PS, Kelley JA, Barchi JJ Jr (1991) Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J Med Chem 34:3280–3284

    PubMed  CAS  Google Scholar 

  • Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148–1159

    PubMed  CAS  Google Scholar 

  • Fathallah H, Atweh GF (2006) DNA hypomethylation therapy for hemoglobin disorders: molecular mechanisms and clinical application. Blood Rev 20:227–234

    PubMed  CAS  Google Scholar 

  • Fathallah H (2008) DNA hypomethylation therapies and hemoglobin disorders. [An interview with Hassana Fathallah by H&O]. Clin Adv Hematol Oncol 6:806–808

    PubMed  Google Scholar 

  • Fiskus W, Buckley K, Rao R, Mandawat A, Yang Y, Joshi R, Wang Y, Balusu R, Chen J, Koul S, Joshi A, Upadhyay S, Atadja P, Bhalla KN (2009) Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol Ther 8:939–950

    PubMed Central  PubMed  CAS  Google Scholar 

  • Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, Plass C, Niemeyer CM, Lübbert M (2009) The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23:1019–1028

    PubMed  CAS  Google Scholar 

  • Garcia-Manero G, Jeha S, Daniel J, Williamson J, Albitar M, Kantarjian HM, Issa JP (2003) Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. Cancer 3:695–702

    Google Scholar 

  • Garcia-Manero G, Issa JP (2005) Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest 23:635–642

    PubMed  CAS  Google Scholar 

  • Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O’brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP (2006) Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271–3279

    PubMed Central  PubMed  CAS  Google Scholar 

  • Garcia-Manero G, Yang H, Kuang SQ, O’Brien S, Thomas D, Kantarjian H (2009) Epigenetics of acute lymphocytic leukemia. Semin Hematol 46:24–32

    PubMed  CAS  Google Scholar 

  • Gattei V, Fonsatti E, Sigalotti L, Degan M, Di Giacomo AM, Altomonte M, Calabro L, Maio M (2005) Epigenetic immunomodulation of hematopoietic malignancies. Semin Oncol 32:503–510

    PubMed  CAS  Google Scholar 

  • Giralt S, Davis M, O’Brien S, Van Besien K, Champlin R, De Vos D, Kantarjian H (1997) Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia 11(Suppl 1):32–34

    Google Scholar 

  • Giralt S, Cohen A, Davis M, O’Brien S, Andersson B, Gajewski J, Khouri I, Körbling M, Champlin R, De Vos D, Kantarjian H (1998a) Phase-I/II study of decitabine with allogeneic peripheral blood stem cell transplantation for treatment of relapse after allogeneic progenitor cell transplantation. In: Symposium on methyltransferase inhibitors in hematologic malignancies, Miami, FL, Dec 1998 (abstract)

    Google Scholar 

  • Giralt S, Cohen A, Davis M, O’Brien S, Andersson B, Gajewski J, Khouri I, Körbling M, Champlin R, de Vos D, Kantarjian H (1998b) Phase-I/II trial combining decitabine with busulfan/cyclophosphamide as a conditioning regimen for allogeneic progenitor cell transplantation. In: Symposium on methyltransferase inhibitors in hematologic malignancies, Miami, Dec 1998 (abstract)

    Google Scholar 

  • Gollob JA, Sclambi CJ, Peterson BL, Richmond T, Thoreson M, Moran K, Dressmann HK, Jelinek J, Issa JP (2006) Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 12:4619–4627

    PubMed  CAS  Google Scholar 

  • Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD, Manning J, Jiemjit A, Dover G, Mays A, Zwiebel J, Murgo A, Weng LJ, Herman JG (2006) Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66:6361–6369

    PubMed  CAS  Google Scholar 

  • Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, Zeng G, Wunderlich JR, Nguyen DM, Restifo NP, Schrump DS (2006) De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 66:1105–1113

    PubMed Central  PubMed  CAS  Google Scholar 

  • Hackanson B, Guo Y, Lübbert M (2005) The silence of the genes: epigenetic disturbances in haematopoietic malignancies. Expert Opin Ther Targets 9:45–61

    PubMed  CAS  Google Scholar 

  • Hambach L, Vermeij M, Buser A, Aghai Z, van der Kwast T, Goulmy E (2008) Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors. Blood 112:1844–1852

    PubMed  CAS  Google Scholar 

  • Hambach L, Ling KW, Pool J, Aghai Z, Blokland E, Tanke HJ, Bruijn JA, Halfwerk H, van Boven H, Wieles B, Goulmy E (2009) Hypomethylation drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. Blood 113:2715–2722

    PubMed  CAS  Google Scholar 

  • Herranz M, Martin-Caballero J, Fraga MF, Ruiz-Cabello J, Flores JM, Desco M, Marquez VE, Esteller M (2006) The novel DNA methylation inhibitor zebularine is effective against the development of T-cell lymphoma. Blood 107:1174–1177

    PubMed  CAS  Google Scholar 

  • Hoshino K, Quintás-Cardama A, Yang H, Sanchez-Gonzalez B, Garcia-Manero G (2007) Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia. Leukemia 21:906–911

    PubMed  CAS  Google Scholar 

  • Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER, Gibson BE, Creutzig U, Zwaan CM, Cloos J, Kuik DJ, Pieters R, Kaspers GJ (2005) The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 93:1388–1394

    PubMed Central  PubMed  CAS  Google Scholar 

  • Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM (2005) Phase II study of low dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23:3948–3956

    PubMed  CAS  Google Scholar 

  • Jones LC, Tefferi A, Idos GE, Kumagai T, Hofmann WK, Koeffler HP (2004) RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia. Oncogene 23:7846–7853

    PubMed  CAS  Google Scholar 

  • Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–692

    PubMed Central  PubMed  CAS  Google Scholar 

  • Kantarjian HM, O’Brien SM, Estey E, Giralt S, Beran M, Rios MB, Keating M, De Vos D, Talpaz M (1997a) Decitabine studies in chronic and acute myelogenous leukemia. Leukemia 11(1):35–36

    Google Scholar 

  • Kantarjian HM, O’Brien SM, Keating M, Beran M, Estey E, Giralt S, Kornblau S, Rios MB, De Vos D, Talpaz M (1997b) Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 11:1617–1620

    PubMed  CAS  Google Scholar 

  • Kantarjian HM, O’Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M (2003) Results of decitabine (5-aza-2′-deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98:522–528

    PubMed  CAS  Google Scholar 

  • Kantarjian HM, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794–1803

    PubMed  CAS  Google Scholar 

  • Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C (2012a) Multicenter, randomized open-label phase III trial of decitabine versus patient choice, with physician advice of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670–2677

    PubMed  CAS  Google Scholar 

  • Kantarjian HM, Roboz GJ, Rizzieri DA, Stock W, O’Connell CL, Griffiths EA (2012b) Results from the dose escalation phase of a randomized phase 1-2 first-in-human (FIH) study of SGI-110, a novel low volume stable subcutaneous (SQ) second generation hypomethylating agent (HMA) in patients with relapsed/refractory MDS and AML. Blood 120: ASH annual meeting abstract number 414

    Google Scholar 

  • Knuth A, Jäger D, Jäger E (2000) Cancer immunotherapy in clinical oncology. Cancer Chemother Pharmacol 46:S46–S51

    PubMed  CAS  Google Scholar 

  • Koshy M, Dorn L, Bressler L, Molokie R, Lavelle D, Talischy N, Hoffman R, van Overveld W, DeSimone J (2000) 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 96:2379–2384

    PubMed  CAS  Google Scholar 

  • Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, Fang ZH, Wei Y, Jelinek J, Issa JP, Garcia-Manero G (2008) Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphoblastic leukemia. Leukemia 8:1529–1538

    Google Scholar 

  • Laliberté J, Marquez VE, Momparler RL (1992) Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol 30:7–11

    PubMed  Google Scholar 

  • Lavelle DE (2004) The molecular mechanism of fetal hemoglobin reactivation. Semin Hematol 41:3–10

    PubMed  CAS  Google Scholar 

  • Lavelle D, Chin J, Vaitkus K, Redkar S, Phiasivongsa P, Tang C, Will R, Hankewych M, Roxas B, Singh M, Saunthararajah Y, Desimone J (2007) Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis. Am J Hematol 82:981–985

    PubMed  CAS  Google Scholar 

  • Lemaire M, Momparler LF, Bernstein ML, Marquez VE, Momparler RL (2005) Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia. Anticancer Drugs 16:301–308

    PubMed  CAS  Google Scholar 

  • Lemaire M, Momparler LF, Raynal NJM, Bernstein ML, Momparler RL (2009) Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 63:411–416

    PubMed  CAS  Google Scholar 

  • Lübbert M (2000) DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 249:135–164

    PubMed  Google Scholar 

  • Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 114:349–357

    PubMed  Google Scholar 

  • Lübbert M, Bertz H, Rüter B, Marks R, Claus R, Wäsch R, Finke J (2009) Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML-patients. Bone Marrow Transplant 44:585–588

    PubMed  Google Scholar 

  • Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW (2011) Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 29:1987–1996

    PubMed  Google Scholar 

  • Lübbert M, Rüter BH, Claus R, Schmoor C, Schmid M, Germing U, Kuendgen A, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, Heil G, Hackanson B, Deschler B, Döhner K, Hagemeijer A, Wijermans PW, Döhner H (2012) A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 97:393–401

    PubMed Central  PubMed  Google Scholar 

  • Lübbert M, Bertz H, Müller MJ, Finke J (2013) When azanucleoside treatment can be curative: nonintensive bridging strategy before allografting in older patients with myelodysplastic syndrome/acute myeloid leukemia. J Clin Oncol 31:822–823

    PubMed  Google Scholar 

  • Marquez VE, Kelley JA, Agbaria R, Ben-Kasus T, Cheng JC, Yoo CB, Jones PA (2005) Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann NY Acad Sci 1058:246–254

    PubMed  CAS  Google Scholar 

  • Maslak P, Chanel S, Camacho LH, Soignet S, Pandolfi PP, Guernah I, Warrell R, Nimer S (2006) Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 2:212–217

    Google Scholar 

  • Momparler RL, Derse D (1979) Kinetics of phosphorylation of 5-aza-2′-deoxycytidine by deoxycytidine kinase. Biochem Pharmacol 28:1443–1444

    PubMed  CAS  Google Scholar 

  • Momparler RL, Bouchard J, Samson J (1985a) Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-aza-2′-deoxycytidine. Leuk Res 9:1361–1366

    PubMed  CAS  Google Scholar 

  • Momparler RL, Rivard GE, Gyger M (1985b) Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia. Pharmacol Ther 30:277–286

    PubMed  CAS  Google Scholar 

  • Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J (1997) Pilot phase-I-II study on 5-aza-2′-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8:358–368

    PubMed  CAS  Google Scholar 

  • Montero AJ, Diaz-Montero CM, Mao L, Youssef EM, Estecio M, Shen L, Issa JP (2006) Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer. Cancer Biol Ther 5:1494–1501

    PubMed  CAS  Google Scholar 

  • Mund C, Brueckner B, Lyko F (2006) Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. Epigenetics 1:7–13

    PubMed  Google Scholar 

  • Odenike OM, Godwin JE, van Besien K, Huo D, Stiff PJ, Sher D, Klekowski N, Green M, Larson RA, Stock W (2006) Phase II study of decitabine in myelofibrosis with myeloid metaplasia. Blood 108: 317b (abstract 4923)

    Google Scholar 

  • Oi S, Natsume A, Ito M, Kondo Y, Shimato S, Maeda Y, Saito K, Wakabayashi T (2009) Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2′-deoxycytidine in glioma cells. J Neurooncol 92:15–22

    PubMed  CAS  Google Scholar 

  • Oki Y, Kantarjian H, Gharibyan V, Jones D, O’brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JP (2007) Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 109:899–906

    PubMed  CAS  Google Scholar 

  • Petti MC, Mandelli F, Zagonel V, De Gregoris C, Merola MC, Latagliata R, Gattei V, Fazi P, Monfardini S, Pino A (1993) Pilot study of 5-aza-2′-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 7:36–41

    PubMed  Google Scholar 

  • Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP (1984) 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64:922–929

    PubMed  CAS  Google Scholar 

  • Pinto A, Zagonel V, Attadia V, Bullian PL, Gattei V, Carbone A, Monfardini S, Colombatti A (1989) 5-Aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 4(Suppl 3):28–32

    PubMed  Google Scholar 

  • Pliml J, Sorm F (1964) Synthesis of 2′-deoxy-D-ribofuranosyl-5-azacytosine. Coll Czeck Chem Commun 29:2576–2577

    CAS  Google Scholar 

  • Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R (2000) Reversal of drug resistance in human tumor xenografts by 2′deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60:6039–6044

    PubMed  CAS  Google Scholar 

  • Pohlmann P, DiLeone LP, Cancella AI, Caldas AP, Dal Lago L, Campos O Jr, Monega E, Rivoire W, Schwartsmann G (2002) Phase II trial of cisplatin plus decitabine, a new hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 25:496–501

    PubMed  Google Scholar 

  • Ravandi F, Kantarjian H, Cohen A, Davis M, O’Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, de Vos D, Champlin R, Giralt S (2001) Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 27:1221–1225

    PubMed  CAS  Google Scholar 

  • Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R (1991) The antileukemic activity of 5-aza-2′-deoxycytidine (Aza-dC) in patients with relapsed and resistant leukemia. Br J Cancer 64:144–148

    PubMed Central  PubMed  CAS  Google Scholar 

  • Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, Lin K, Momparler LF (1981) Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 5:453–462

    PubMed  CAS  Google Scholar 

  • Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro G, Molina FJ, Calasanz MJ, Prosper F, Heiniger A, Torres A (2004) Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 10:2492–2498

    Google Scholar 

  • Roman-Gomez J, Cordeu L, Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, Garate L, Calasanz MJ, Heiniger A, Torres A, Prosper F (2007) Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 8:3462–3469

    Google Scholar 

  • Rüter B, Wijermans PW, Lübbert M (2006) Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2′-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 106:1744–1750

    PubMed  Google Scholar 

  • Sacchi S, Talpaz M, O’Brien S, Cortes J, Kantarjian HM (1998) Decitabine, a hypomethylating agent, is active for the treatment of chronic myelogenous leukemia (CML) in non-lymphoid blastic phase (BP). Blood 92 (Suppl 1): 252a (abstract)

    Google Scholar 

  • Sacchi S, Kantarjian HM, O’Brien S, Cortes J, Rios MB, Giles FJ, Beran M, Koller CA, Keating MJ, Talpaz M (1999) Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86:2632–2641

    PubMed  CAS  Google Scholar 

  • Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, Wheeler R, Boucher K, Fitzpatrick F, Jones DA, Karpf AR (2005) Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 23:3897–3905

    PubMed  CAS  Google Scholar 

  • Santi DV, Garret CD, Barr PJ (1983) On the mechanism of inhibition of DNA-cytosine methyltransferase by cytidine analogs. Cell 83:83–89

    Google Scholar 

  • Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler L, Gavazova S, Chen YH, Hoffman R, DeSimone J (2003) Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 102:3865–3870

    PubMed  CAS  Google Scholar 

  • Saunthararajah Y (2007) Decitabine and sickle cell disease: molecular therapy for a molecular disease. Pediatr Hematol Oncol 24:465–468

    PubMed  CAS  Google Scholar 

  • Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J (2008) Clinical effectiveness of decitabine in severe sickle cell disease. Br J Haematol 141:126–129

    PubMed  Google Scholar 

  • Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Pishchik V, Figg WD, Murgo AJ, Steinberg SM (2006) Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 12:5777–5785

    PubMed  CAS  Google Scholar 

  • Schwartsmann G, Fernandes MS, Schaan MD, Moschen M, Gerhardt LM, DiLeone L, Loitzembauer B, Kalakun L (1997) Decitabine (5-aza-2′-deoxycytidine; decitabine) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Leukemia 11(Suppl 1):28–31

    Google Scholar 

  • Schwartsmann G, Schunemann H, Gorini CN, Filho AF, Garbino C, Sabini G, Muse I, DiLeone L, Mans DR (2000) A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 18:83–91

    PubMed  CAS  Google Scholar 

  • Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR, DeCoteau JF (2007) Zebularine inhibits human acute myeloid leukemia cell growth vitro in association with p15INK4B demethylation and reexpression. Exp Hematol 35:263–273

    PubMed  CAS  Google Scholar 

  • Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, Imai K, Kantarjian HM, Issa JP, Garcia-Manero G (2003) Aberrant DNA methylation of p57KIP2 identifies a cell cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 101:4131–4136

    PubMed  CAS  Google Scholar 

  • Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP (2010) DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28:605–613

    PubMed Central  PubMed  CAS  Google Scholar 

  • Shi J, Zhao Y, Ishii T, Hu W, Sozer S, Zhang W, Bruno E, Lindgren V, Xu M, Hoffman R (2007) Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res 67:6417–6424

    PubMed  CAS  Google Scholar 

  • Sigalotti L, Coral S, Nardi G, Spessotto A, Cortini E, Cattarossi I, Colizzi F, Altomonte M, Maio M (2002) Promoter methylation controls the expression fo MAGE2, 3 and 4 genes in human cutaneous melanoma. J Immunother 25:16–26

    PubMed  CAS  Google Scholar 

  • Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M, Maio M (2004) Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine. Cancer Res 64:9167–9171

    PubMed  CAS  Google Scholar 

  • Sigalotti L, Coral S, Fratta E, Lamaj E, Danielli R, Di Giacomo AM, Altomonte M, Maio M (2005) Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. Semin Oncol 32:473–478

    PubMed  CAS  Google Scholar 

  • Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G (2007) Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110:2302–2308

    PubMed  CAS  Google Scholar 

  • Stathis A, Hotte SJ, Chen EX, Hirte HW, Oza AM, Moretto P, Webster S, Laughlin A, Stayner LA, McGill S, Wang L, Zhang WJ, Espinoza-Delgado I, Holleran JL, Egorin MJ, Siu LL (2011) Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Clin Cancer Res 17:1582–1590

    PubMed  CAS  Google Scholar 

  • Stresemann C, Lyko F (2008) Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 123:8–13

    PubMed  CAS  Google Scholar 

  • Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, Reed E, Samid D (1998) A phase-II study of 5-aza-2′-deoxycytidine (decitabine) in hormone-independent metastatic (D2) prostate cancer. Tumori 84:87–89

    PubMed  CAS  Google Scholar 

  • Trompeter S, Roberts I (2009) Haemoglobin F modulation in childhood sickle cell disease. Brit J Haematol 144:308–316

    CAS  Google Scholar 

  • van den Bosch J, Lübbert M, Verhoef G, Wijermans PW (2004) The effects of 5-aza-2′-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndrome. Leuk Res 28:785–790

    PubMed  Google Scholar 

  • Venturelli S, Armeanu S, Pathil A, Hsieh CJ, Weiss TS, Vonthein R, Wehrmann M, Gregor M, Lauer UM, Bitzer M (2007) Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 109:2132–2141

    PubMed  CAS  Google Scholar 

  • Vermorken JB, Tumolo S, Roozendaal KJ, Guastalla JP, Splinter Ted AW, Renard J (1991) 5-Aza-2′-deoxycytidine in advanced or recurrent cancer of the uterine cervix. Eur J Cancer 27:216–217

    PubMed  CAS  Google Scholar 

  • Wang JC, Chen W, Nallusamy S, Chen C, Novetsky AD (2002) Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Brit J Haematol 116:582–586

    CAS  Google Scholar 

  • Wang WC (2008) The pharmacotherapy of sickle cell disease. Expert Opin Pharmacother 9:3069–3082

    PubMed  CAS  Google Scholar 

  • Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J, Rosenberg SA (1994) Expression of the MAGE-I tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res 54:1766–1771

    PubMed  CAS  Google Scholar 

  • Wijermans PW, Krulder JW, Huijgens PC, Neve P (1997) Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11:19–23

    Google Scholar 

  • Wijermans PW, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2000) Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18:956–962

    PubMed  CAS  Google Scholar 

  • Wijermans PW, Lübbert M, Verhoef G, Klimek V, Bosly A (2005) An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 84(Suppl 1):9–17

    PubMed  CAS  Google Scholar 

  • Willemze R, Archimbaud E, Muus P (1993) Preliminary results with 5-aza-2′deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. Leukemia 7(Suppl 1):49–50

    PubMed  Google Scholar 

  • Willemze R, Suciu S, Archimbaud E, Muus P, Stryckmans P, Louwagie EA, Berneman Z, Tjean M, Wijermans P, Döhner H, Jehn U, Labar B, Jaksic B, Dardenne M, Zittoun R (1997) A randomized phase-II study on the effects of 5-aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase-II study. Leukemia 11(Suppl 1):24–27

    Google Scholar 

  • Wilson VL, Jones PA, Momparler RL (1983) Inhibition of DNA methylation in L1210 leukemia cells by 5-aza-2′-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res 43:3493–3496

    PubMed  CAS  Google Scholar 

  • Yanez L, Bermudez A, Richard C, Bureo E, Iriondo A (2009) Letter to the editor: Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia. Leukemia 23:1342–1343

    PubMed  CAS  Google Scholar 

  • Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, Kantarjian HM, Garcia-Manero G, Issa JP (2006) DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 66:5495–5503

    PubMed  CAS  Google Scholar 

  • Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G (2005) Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res 29:739–748

    PubMed  CAS  Google Scholar 

  • Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O’Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G (2009) Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood 113:1892–1898

    PubMed Central  PubMed  CAS  Google Scholar 

  • Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5:37–50

    PubMed  CAS  Google Scholar 

  • Zagonel V, Pinto A, Bullian PL, Sorio R, Gattei V, Curri G, De Rosa L, Attadia V, Monfardini S (1990) 5-Aza-2′-deoxycytidine as a differentiation inducer in human hemopoietic malignancies: preliminary clinical report. In: Momparler RL, de Vos D (eds) PCH 5-Aza-2′-deoxycytidine: preclinical and clinical studies. Haarlem, Netherlands, pp 165–181

    Google Scholar 

  • Zagonel V, Lo Re G, Marotta G, Barbare R, Sardeo R, Gattei V, de Angelis V, Montardinni S, Pinto A (1993) 5-Aza-2′-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndrome. Leukemia 7(Suppl 1):30–35

    PubMed  Google Scholar 

  • Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP (2002) Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 23:591–599

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Freiburg, Germany

    Björn Hackanson

  2. Bern, Switzerland

    Michael Daskalakis

Authors
  1. Björn Hackanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Daskalakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Björn Hackanson .

Editor information

Editors and Affiliations

  1. Cancer Center Heilbronn-Franken, SLK-Kliniken Heilbronn GmbH Medizinische Klinik III, Heilbronn, Germany

    Uwe M. Martens

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hackanson, B., Daskalakis, M. (2014). Decitabine. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 201. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54490-3_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54490-3_18

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54489-7

  • Online ISBN: 978-3-642-54490-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation